Clinical Challenges

Noninfectious Pneumonitis in a Patient With Renal Cell Carcinoma Treated With Everolimus

Patricia A. Creel

Nancy P. Moldawer

pneumonia, radiation pneumonitis, renal cell carcinoma
ONF 2011, 38(2), 125-128. DOI: 10.1188/11.ONF.125-128

Jump to a section

    References

    Amato, R. J., Jac, J., Giessinger, S., Saxena, S., & Willis, J. P. (2009). A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer, 115, 2438-2446. doi: 10.1002/cncr.24280
    Atkins, M. B., Hidalgo, M., Stadler, W. M., Logan, T. F., Dutcher, J. P., Hudes, G. R., … Sherman, M. L. (2004). Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. Journal of Clinical Oncology, 22, 909-918. doi: 10.1200/JCO.2004.08.185
    Bellmunt, J., Szczylik, C., Feingold, J., Strahs, A., & Berkenblit, A. (2008). Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Annals of Oncology, 19, 1387-1392. doi: 10.1093/annonc/mdn066
    Champion, L., Stern, M., Israël-Biet, D., Mamzer-Bruneel, M. F., Peraldi, M. N., Kreis, H., … Morelon, E. (2006). Brief communication: Sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Annals of Internal Medicine, 144, 505-509.
    Duran, I., Kortmansky, J., Singh, D., Hirte, H., Kocha, W., Goss, G., … Siu, L. L. (2006). A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. British Journal of Cancer, 95, 1148-1154. doi: 10.1038/sj.bjc.6603419
    Duran, I., Siu, L. L., Oza, A. M., Chung, T. B., Sturgeon, J., Townsley, C. A., … Niroumand, M. (2006). Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. European Journal of Cancer, 42, 1875-1880. doi: 10.1016/j.ejca.2006.03.015
    Ellard, S. L., Clemons, M., Gelmon, K. A., Norris, B., Kennecke, H., Chia, S., … Seymour, L. (2009). Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. Journal of Clinical Oncology, 27, 4536-4541.
    Hudes, G. (2010). Pulmonary toxicity of the rapamycin analog class of mTOR inhibitors. Kidney Cancer Journal, 8, 21-24.
    Lennon, A., Finan, K., FitzGerald, M. X., & McCormick, P. A. (2001). Interstitial pneumonitis associated with sirolimus (rapamycin) therapy after liver transplantation. Transplantation, 72, 1166-1167. doi: 10.1097/00007890-200109270-00034
    Morelon, E., Stern, M., Israël-Biet, D., Correas, J. M., Danel, C., Mamzer-Bruneel, M. F. … Kreis, H. (2001). Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation, 72, 787-790. doi: 10.1097/00007890-200109150-00008
    Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., … Ravaud, A. (2010). Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer, 116, 4256-4265. doi: 10.1002/cncr.25219
    National Cancer Institute. (2006). Common Terminology Criteria for Adverse Events [v.3.0]. Retrieved from http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf
    National Cancer Institute. (2010). Common Terminology Criteria for Adverse Events [v.4.0]. Retrieved from http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
    National Comprehensive Cancer Network. (2010). Clinical Practice Guidelines in Oncology™: Kidney cancer [v.2.2010]. Retrieved from http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
    Novartis Pharmaceuticals Corporation. (2009). Afinitor® [Prescribing information]. East Hanover, NJ: Author.
    Pham, P. T., Pham, P. C., Danovitch, G. M., Ross, D. J., Gritsch, H. A., Kendrick, E. A., … Wilkinson, A. H. (2004). Sirolimus-associated pulmonary toxicity. Transplantation, 77, 1215-1220.
    Sankhala, K., Mita, A., Kelly, K., Mahalingam, D., Giles, F., & Mita, M. (2009). The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Targeted Oncology, 4, 135-142. doi: 10.1007/s11523-009-0107-z
    Thomson, A. W., Turnquist, H. R., & Raimondi, G. (2009). Immunoregulatory functions of mTOR inhibition. Nature Reviews Immunology, 9, 324-337. doi: 10.1038/nri2546
    Vahid, B., & Marik, P. E. (2008). Pulmonary complications of novel antineoplastic agents for solid tumors. Chest, 133, 528-538.
    Duran, I., Kortmansky, J., Singh, D., Hirte, H., Kocha, W., Goss, G., … Siu, L. L. (2006). A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. British Journal of Cancer, 95, 1148-1154.
    Duran, I., Siu, L. L., Oza, A. M., Chung, T. B., Sturgeon, J., Townsley, C. A., … Niroumand, M. (2006). Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. European Journal of Cancer, 42, 1875-1880.
    Ellard, S. L., Clemons, M., Gelmon, K. A., Norris, B., Kennecke, H., Chia, S., … Seymour, L. (2009). Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. Journal of Clinical Oncology, 27, 4536-4541.
    Hudes, G. (2010). Pulmonary toxicity of the rapamycin analog class of mTOR inhibitors. Kidney Cancer Journal, 8, 21-24.
    Morelon, E., Stern, M., Israël-Biet, D., Correas, J. M., Danel, C., Mamzer-Bruneel, M. F., … Kreis, H. (2001). Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation, 72, 787-790.
    National Cancer Institute. (2010). Common Terminology Criteria for Adverse Events [v.4.0]. Retrieved from http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
    Novartis Pharmaceuticals Corporation. (2009). Afinitor® [Prescribing information]. East Hanover, NJ: Author.
    Pham, P. T., Pham, P. C., Danovitch, G. M., Ross, D. J., Gritsch, H. A., Kendrick, E. A., … Wilkinson, A. H. (2004). Sirolimus-associated pulmonary toxicity. Transplantation, 77, 1215-1220.
    Sankhala, K., Mita, A., Kelly, K., Mahalingam, D., Giles, F., & Mita, M. (2009). The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Targeted Oncology, 4, 135-142.
    Vahid, B., & Marik, P. E. (2008). Pulmonary complications of novel antineoplastic agents. Chest, 133, 528-538.